Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients (Q34975825)

5 August 2017

title

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients (English)

1 reference

5 August 2017

1 reference

10

Hassan Errihani

1 reference

5 August 2017

Meryem Aitelhaj

1

1 reference

5 August 2017

Siham Lkhouyaali

2

1 reference

5 August 2017

Ghizlane Rais

3

1 reference

5 August 2017

Amina Mohtaram

4

1 reference

5 August 2017

Soundouss Raissouni

5

1 reference

5 August 2017

Brahim Ghissassi

6

1 reference

5 August 2017

Saber Boutayeb

7

1 reference

5 August 2017

Hind Mrabti

8

1 reference

5 August 2017

Youssef Bensouda

9

1 reference

5 August 2017

publication date

28 August 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

6

1 reference

5 August 2017

page(s)

339

1 reference

Creative Commons Attribution 2.0 Generic

5 August 2017

copyright license

start time

28 August 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

MTHFR polymorphisms and breast cancer risk.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab-induced cardiotoxicity: heart failure at the crossroads

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab--mechanism of action and use in clinical practice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Reducing the global breast cancer burden: the importance of patterns of care research

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

The global breast cancer burden: variations in epidemiology and survival.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765764

The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-0500-6-339

Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-0500-6-339

Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1756-0500-6-339

The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients

21 January 2018

1 reference

12 December 2020

Cardiotoxicity of trastuzumab in clinical practice

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-0500-6-339

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference